Zafirlukast for Ovarian Cancer

Palo Alto (17 mi)

Overseen byJeffrey Zwicker, MD

Age: 18+

Sex: Female

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Beth Israel Deaconess Medical Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing Zafirlukast, an asthma medication, to see if it can help patients with relapsed ovarian cancer. The drug may reduce tumor activity and lower the risk of blood clots based on lab studies. Zafirlukast is commonly used to improve asthma control.

Eligibility Criteria

This trial is for adult women with a specific type of ovarian cancer that has relapsed, indicated only by tumor markers without visible disease. They must have finished initial chemotherapy and surgery successfully, be able to swallow pills, and use contraception if childbearing potential. Men and those with certain health conditions or on conflicting medications are excluded.

Inclusion Criteria

I am 18 years old or older.

My CA-125 levels have doubled without signs of cancer on scans.

I can swallow pills.

I am 18 years old or older.

I have been diagnosed with ovarian, fallopian tube, or peritoneal cancer.

My blood counts and kidney and liver functions are within normal ranges.

I can take care of myself but might not be able to do heavy physical work.

Exclusion Criteria

I am not pregnant or breastfeeding.

I am currently on blood thinner medication.

I am not taking any drugs that affect CYP2C9 enzyme activity.

I do not have brain metastases.

Treatment Details

The study tests Zafirlukast's effectiveness in preventing tumor activity in women whose ovarian cancer has returned but is only detectable through tumor markers rather than physical tumors. Participants will take Zafirlukast tablets to see if it can control the cancer's return.

1Treatment groups

Experimental Treatment

Group I: ZafirlukastExperimental Treatment1 Intervention

Zafirlukast will be taken orally at a pre-determined dose 2x daily for 28 day cycle up to 1 year.